The qualitative and quantitative upregulation of the expression of the CTLA-4 molecule (both surface and cytoplasmic) observed by us in peripheral BTLA+ T cells in CLL may reflect a powerful suppression of T cell effector functions, including antitumor and anti-inflammatory activities. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.